The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Li, Hongtao ^a   Min, Daliu ^a   Zhao, Hui ^a   Wang, Zhiyu ^a   Qi, Weixiang ^a   Zheng, Shuier ^a   Tang, Lina ^a   He, Aina ^a   Sun, Yuanjue ^a   Yao, Yang ^a   Shen, Zan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; EZRIN; CYTOSKELETON PROTEIN; TUMOR PROTEIN;

ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG RESPONSE; EVENT FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; META ANALYSIS; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; BONE TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; MALE; MEDLINE; METABOLISM; MORTALITY; SURVIVAL RATE;

BONE NEOPLASMS; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEDLINE; NEOPLASM PROTEINS; OSTEOSARCOMA; SURVIVAL RATE;

EID: 84879252276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064513     Document Type: Review

References (31)

1. Picci P, (2007) Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2: 6.
2. Meyers PA, Gorlick R, (1997) Osteosarcoma. Pediatr Clin North Am 44: 973-989.
3. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, et al. (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106: 1154-1161.
4. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, et al. (1986) The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314: 1600-1606.
5. Clark JC, Dass CR, Choong PF, (2008) A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297.
6. Bakhshi S, Radhakrishnan V, (2010) Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 10: 271-287.
7. Bretscher A, Edwards K, Fehon RG, (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3: 586-599.
8. Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M, (2003) Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol Biol Cell 14: 2181-2191.
9. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, et al. (2006) Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis 23: 227-236.
10. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, et al. (2004) The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nature medicine 10: 182-186.
11. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M, (2005) The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7: R365-373.
12. Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkila S, et al. (2008) Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol 39: 1737-1743.
13. Geiger KD, Stoldt P, Schlote W, Derouiche A, (2000) Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas. Am J Pathol 157: 1785-1793.
14. Makitie T, Carpen O, Vaheri A, Kivela T, (2001) Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci 42: 2442-2449.
15. Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R, et al. (2003) Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol 90: 273-281.
16. Weng WH, Ahlen J, Astrom K, Lui WO, Larsson C, (2005) Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas. Clin Cancer Res 11: 6198-6204.
17. Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, et al. (2009) Expression of Ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clinical and Investigative Medicine Médecine Clinique Et Experimentale 32: E180-188.
18. Boldrini E, Peres SV, Morini S, de Camargo B, (2010) Immunoexpression of Ezrin and CD44 in patients with osteosarcoma. Journal of pediatric hematology/oncology: official journal of the American Society of Pediatric Hematology/Oncology 32: e213-217.
19. Ferrari S, Zanella L, Alberghini M, Palmerini E, Staals E, et al. (2008) Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma. Pediatric blood & cancer 50: 752-756.
20. Kim C, Shin E, Hong S, Chon HJ, Kim HR, et al. (2009) Clinical value of ezrin expression in primary osteosarcoma. Cancer research and treatment: official journal of Korean Cancer Association 41: 138-144.
21. Kim MS, Song WS, Cho WH, Lee SY, Jeon DG, (2007) Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 459: 229-236.
22. Park HR, Jung WW, Bacchini P, Bertoni F, Kim YW, et al. (2006) Ezrin in osteosarcoma: comparison between conventional high-grade and central low-grade osteosarcoma. Pathology, research and practice 202: 509-515.
23. Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, et al. (2007) Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Archiv: an international journal of pathology 451: 999-1007.
24. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-2834.
25. DerSimonian R, (1996) Meta-analysis in the design and monitoring of clinical trials. Stat Med 15: 1237-1248 discussion 1249-1252.
26. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
27. Bax L, Ikeda N, Fukui N, Yaju Y, Tsuruta H, et al. (2009) More than numbers: the power of graphs in meta-analysis. Am J Epidemiol 169: 249-255.
28. Wells G, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.
29. Mirabello L, Troisi RJ, Savage SA, (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
30. Brambilla D, Zamboni S, Federici C, Lugini L, Lozupone F, et al. (2012) P-glycoprotein binds to ezrin at amino acid residues 149-242 in the FERM domain and plays a key role in the multidrug resistance of human osteosarcoma. Int J Cancer 130: 2824-2834.
31. Wu KL, Khan S, Lakhe-Reddy S, Jarad G, Mukherjee A, et al. (2004) The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival. J Biol Chem 279: 26280-26286.